BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) Insider Lai Wang Sells 1,028 Shares

BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) insider Lai Wang sold 1,028 shares of the firm’s stock in a transaction that occurred on Monday, June 23rd. The stock was sold at an average price of $260.00, for a total transaction of $267,280.00. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Lai Wang also recently made the following trade(s):

• On Tuesday, June 17th, Lai Wang sold 470 shares of BeOne Medicines stock. The stock was sold at an average price of $251.37, for a total value of $118,143.90.
• On Monday, June 16th, Lai Wang sold 1,177 shares of BeOne Medicines stock. The shares were sold at an average price of $266.40, for a total transaction of $313,552.80.
• On Friday, June 6th, Lai Wang sold 1,402 shares of BeOne Medicines stock. The stock was sold at an average price of $252.39, for a total transaction of $353,850.78.

BeOne Medicines Trading Up 0.1%

Shares of NASDAQ ONC opened at $267.13 on Thursday. The company has a current ratio of 1.96, a quick ratio of 1.71 and a debt-to-equity ratio of 0.05. The firm’s fifty day moving average price is $247.22. BeOne Medicines Ltd. – Sponsored ADR has a 1-year low of $141.31 and a 1-year high of $287.88. The company has a market capitalization of $29.28 billion, a price-to-earnings ratio of -71.81 and a beta of 0.30.

BeOne Medicines (NASDAQ:ONC) last posted its quarterly earnings results on Wednesday, May 7th. The company reported $1.22 earnings per share for the quarter, topping the consensus estimate of ($0.71) by $1.93. BeOne Medicines had a negative return on equity of 7.55% and a negative net margin of 9.40%. The company had revenue of $1.12 billion during the quarter, compared to the consensus estimate of $1.12 billion. Analysts forecast that BeOne Medicines Ltd. – Sponsored ADR will post -5.82 EPS for the current year.

Analysts Set New Price Targets

Several brokerages have recently commented on ONC. TD Securities reaffirmed a “buy” rating and set a $334.00 price objective on shares of BeOne Medicines in a research report on Thursday, April 24th. Wall Street Zen upgraded shares of BeOne Medicines from a “hold” rating to a “buy” rating in a report on Thursday, May 22nd. Bank of America upgraded shares of BeOne Medicines from a “neutral” rating to a “buy” rating and upped their price objective for the company from $207.00 to $320.00 in a report on Monday, March 3rd. Macquarie raised their target price on BeOne Medicines from $259.00 to $313.00 and gave the company an “outperform” rating in a research note on Friday, February 28th. Finally, JMP Securities set a $348.00 target price on BeOne Medicines in a research report on Friday, February 28th. Seven investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus price target of $319.00.

About BeOne Medicines

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations.